Equillium, Inc. experienced a significant net loss of $8.654 million in the first quarter of 2025, with no revenue generated during this period. The company's operating expenses decreased, primarily due to a wind-down of clinical studies and CMC activities. The company's cash and cash equivalents stood at $14.502 million as of March 31, 2025, and management believes these funds will be sufficient to fund operations into the third quarter of 2025.

Equillium reported Q4 2024 revenue of $4.4 million, a decrease from $9.2 million in Q4 2023. The company's net loss for the quarter was $5.8 million, or $(0.16) per share, compared to a net loss of $2.3 million, or $(0.07) per share, in the same period last year. Despite not meeting primary endpoints in the EQUATOR study, itolizumab showed statistically significant and clinically meaningful benefits in longer-term outcomes, leading to a Breakthrough Therapy designation request and a planned FDA meeting.

Equillium reported revenue of $12.2 million for the third quarter of 2024, compared to $8.9 million for the same period in 2023. Net loss for the quarter was approximately $7,000, or $(0.00) per basic and diluted share, compared to a net loss of $3.7 million, or $(0.11) per basic and diluted share, for the same period in 2023.

Equillium reported a net income of $0.5 million for the second quarter of 2024, a significant improvement compared to the net loss of $3.3 million in the same period of 2023. Revenue increased to $13.9 million, driven by itolizumab development funding and amortization of the upfront payment. The company's cash balance increased to $33.3 million.

Equillium reported revenue of $10.7 million and a net loss of $2.7 million for the first quarter of 2024. The company's cash balance was $32.3 million as of March 31, 2024, expected to provide cash runway into 2H 2025.

Equillium reported a revenue of $9.2 million for Q4 2023, compared to $15.8 million for the same period in 2022. Net loss for the quarter was $2.3 million, or $(0.07) per basic and diluted share, compared with net income of $2.8 million, or $0.08 per basic and diluted share for the same period in 2022. The company's cash balance at the end of 2023 was $40.9 million, expected to provide cash runway into 2H 2025.

Equillium announced positive data from the Type B portion of the EQUALISE study in lupus nephritis patients. The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added to mycophenolate mofetil (MMF) and corticosteroids.

Equillium reported revenue of $9.1 million for Q2 2023, derived from itolizumab development funding from Ono Pharmaceutical Co, Ltd, and a net loss of $3.3 million, or $(0.10) per basic and diluted share. The company's cash, cash equivalents, and short-term investments totaled $48.4 million as of June 30, 2023, expected to fund operations into 2025.

Equillium reported revenue of $8.9 million for the first quarter of 2023, derived from itolizumab development funding and amortization of the upfront payment from Ono Pharmaceutical Co, Ltd. The company's net loss for the quarter was $3.9 million, or $(0.11) per share. Cash, cash equivalents and short-term investments totaled $62.0 million as of March 31, 2023, expected to fund operations into 2025.

Equillium reported Q4 2022 revenue of $15.8 million derived from the asset purchase agreement with Ono, and a net income of $2.8 million, or $0.08 per basic and diluted share. The company's cash balance at the end of 2022 was $71.0 million, expected to provide cash runway into 2025. Equillium also highlighted the acquisition of Bioniz Therapeutics and a strategic partnership with Ono Pharmaceutical.

Equillium reported a net loss of $13.7 million for Q3 2022. The company announced a pending acquisition of Metacrine, expected to add $35 million in cash and extend operating runway into 2024. They also initiated Phase 2 study of EQ101 and Phase 1 study of EQ102.

Equillium's second quarter focused on executing development programs with itolizumab and advancing clinical development of EQ101 and EQ102. The company is preparing to initiate a Phase 2 clinical study of EQ101 in alopecia areata and a Phase 1 SAD/MAD study of EQ102, both expected to commence in the second half of the year. Enrollment continues for the Phase 3 EQUATOR study in acute graft-versus-host disease, with interim data pending from the Phase 1b EQUALISE study of itolizumab in patients with lupus nephritis.

Equillium reported a net loss of $37.4 million, or $(1.17) per basic and diluted share, for the first quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $68.8 million as of March 31, 2022. They also acquired Bioniz Therapeutics, adding two clinical-stage assets to their pipeline.

Equillium announced positive topline data from EQUATE study, initiated EQUATOR Phase 3 study, presented interim safety data from EQUALISE study, and acquired Bioniz Therapeutics. The company's clinical advancements were fueled by itolizumab, and the acquisition expands their pipeline.

Equillium announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease. They also reported a decrease in proteinuria observed in a subgroup of patients with lupus following two doses of itolizumab and interim safety data from the first cohort of asthma patients in the Phase 1b EQUIP study.

Equillium reported second quarter 2021 financial results, highlighted by positive data from the Phase 1b EQUATE study in acute graft-versus-host disease. The company plans to advance to a single, pivotal Phase 3 clinical study.

Equillium reported a net loss of $9.0 million, or $(0.33) per basic and diluted share, for the first quarter of 2021. Research and development expenses were $5.9 million, and general and administrative expenses were $2.8 million. Cash, cash equivalents and short-term investments totaled $104.1 million as of March 31, 2021.

Equillium reported a net loss of $8.9 million for Q4 2020, or $(0.36) per share. Research and development expenses were $6.6 million, and general and administrative expenses were $2.4 million. The company's cash, cash equivalents, and short-term investments totaled $82.2 million as of December 31, 2020.

Equillium reported a net loss of $6.6 million for the third quarter of 2020. They ended the quarter with $90.5 million in cash and investments, strengthened by $53.0 million in net proceeds from financings.

Equillium reported a net loss of $6.5 million for Q2 2020, or $(0.37) per basic and diluted share. The company held $42.6 million in cash, cash equivalents, and short-term investments as of June 30, 2020.

Equillium reported a net loss of $7.8 million, or $(0.45) per basic and diluted share, for the three months ended March 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $47.7 million at March 31, 2020.

Equillium announced its Q4 2019 financial results, highlighted by a net loss of $7.6 million. The company paused enrollment in the EQUIP and EQUALISE trials due to the COVID-19 pandemic but maintained its guidance for initial data from the EQUATE trial in the second half of 2020. They also reiterated that current cash is sufficient to fund operations into the second half of 2021.